{
    "nct_id": "NCT02923466",
    "official_title": "Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNÎ²-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors",
    "inclusion_criteria": "* Be > 18 years of age on day of signing informed consent.\n* Have a histologically confirmed diagnosis of an advanced and/or metastatic solid tumor that is relapsed and/or refractory to standard therapy, as defined as progression on at least one prior line of therapy in the relapsed/metastatic setting and no existing options are felt to provide clinical benefit.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.\n* Adequate hematological, liver and kidney function.\n* Must be willing to implement contraception throughout study and for 120 days after receiving the study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment.\n* Has a history of a bone marrow or solid organ transplant.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.",
    "miscellaneous_criteria": ""
}